###begin article-title 0
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation
###end article-title 0
###begin p 1
###xml 38 67 38 67 <email xmlns:xlink="http://www.w3.org/1999/xlink">richard.pestell@jefferson.edu</email>
Correspondence to Richard G. Pestell: richard.pestell@jefferson.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 241 246 <span type="species:ncbi:9606">human</span>
Decreased expression of specific microRNAs (miRNAs) occurs in human tumors, which suggests a function for miRNAs in tumor suppression. Herein, levels of the miR-17-5p/miR-20a miRNA cluster were inversely correlated to cyclin D1 abundance in human breast tumors and cell lines. MiR-17/20 suppressed breast cancer cell proliferation and tumor colony formation by negatively regulating cyclin D1 translation via a conserved 3' untranslated region miRNA-binding site, thereby inhibiting serum-induced S phase entry. The cell cycle effect of miR-17/20 was abrogated by cyclin D1 siRNA and in cyclin D1-deficient breast cancer cells. Mammary epithelial cell-targeted cyclin D1 expression induced miR-17-5p and miR-20a expression in vivo, and cyclin D1 bound the miR-17/20 cluster promoter regulatory region. In summary, these studies identify a novel cyclin D1/miR-17/20 regulatory feedback loop through which cyclin D1 induces miR-17-5p/miR-20a. In turn, miR-17/20 limits the proliferative function of cyclin D1, thus linking expression of a specific miRNA cluster to the regulation of oncogenesis.
###end p 3
###begin p 4
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
###xml 84 88 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 90 115 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
Abbreviations used in this paper: MEF, mouse embryonic fibroblast; miRNA, microRNA; MMTV, mouse mammary tumor virus; MSCV, mouse stem cell virus; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; UTR, untranslated region.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 443 458 431 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Yi et al., 2003</xref>
###xml 460 477 448 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">Lund et al., 2004</xref>
###xml 479 497 467 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">Zhang et al., 2004</xref>
###xml 676 688 664 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">Ambros, 2004</xref>
###xml 690 702 678 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Cullen, 2004</xref>
###xml 740 749 728 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Lai, 2002</xref>
###xml 1042 1059 1030 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Krek et al., 2005</xref>
###xml 796 802 <span type="species:ncbi:9606">humans</span>
###xml 1029 1034 <span type="species:ncbi:9606">human</span>
MicroRNAs (miRNAs) are 21-22 nucleotide molecules that regulate the stability or translational efficiency of targeted mRNAs. Derived from nuclear precursor RNAs, initial processing occurs by the internuclease Drosha to release pre-miRNAs of 60-70 nucleotides in length from pri-miRNA. Subsequent transport to the cytoplasm by exportin-5 results in processing by the internuclease Dicer to generate the approximately22-nucleotide mature miRNA (Yi et al., 2003; Lund et al., 2004; Zhang et al., 2004). The base pairing interactions between miRNAs and their target mRNAs, often within the 3' untranslated region (UTR) of target genes, results in the degradation of target mRNAs (Ambros, 2004; Cullen, 2004) or inhibition of their translation (Lai, 2002). To date, 533 miRNAs have been identified in humans (miRBase Sequence Database version 10.0, released in August 2007; ). It has been proposed that, as each vertebrate miRNA may bind to as many as 200 gene targets, miRNAs potentially control the expression of about one-third of human mRNAs (Krek et al., 2005).
###end p 6
###begin p 7
###xml 81 99 81 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Calin et al., 2005</xref>
###xml 101 122 101 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Croce and Calin, 2005</xref>
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">2006</xref>
###xml 130 145 130 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">He et al., 2005</xref>
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">2007</xref>
###xml 361 379 361 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">Calin et al., 2004</xref>
###xml 555 578 555 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">Takamizawa et al., 2004</xref>
###xml 646 649 646 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 656 676 656 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Johnson et al., 2005</xref>
###xml 801 819 789 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Calin et al., 2002</xref>
###xml 874 894 862 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Cimmino et al., 2005</xref>
###xml 978 993 966 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">He et al., 2007</xref>
###xml 1156 1181 1144 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Eiriksdottir et al., 1998</xref>
###xml 1183 1199 1171 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Lin et al., 1999</xref>
###xml 1360 1364 1348 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1</italic>
###xml 1396 1399 1384 1387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 1428 1450 1416 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 1572 1594 1560 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Hayashita et al., 2005</xref>
###xml 1596 1611 1584 1599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">He et al., 2005</xref>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
###xml 1000 1005 <span type="species:ncbi:9606">human</span>
###xml 1321 1326 <span type="species:ncbi:9606">human</span>
Several independent lines of evidence support a role for miRNAs in human cancer (Calin et al., 2005; Croce and Calin, 2005, 2006; He et al., 2005, 2007). miRNA-encoding genes are frequently located at fragile sites, as well as in minimal regions of loss of heterozygosity, minimal regions of amplification, and in common breakpoint regions involved in cancers (Calin et al., 2004). Aberrant expression of miRNAs or mutations of miRNA genes have been described in many types of tumors. Let-7 abundance is reduced in several cancers, including lung cancer (Takamizawa et al., 2004), and let-7 was reported to regulate tumor growth by targeting the ras gene (Johnson et al., 2005). miR-15a and miR16-1 were deleted and/or down-regulated in approximately70% of patients with chronic lymphocytic leukemia (Calin et al., 2002). miR-15a/16-1 induced apoptosis by inhibiting BCL-2 (Cimmino et al., 2005). The miR-34 family is an important component of the p53 tumor suppressor network (He et al., 2007). The human miR-17/20 cluster's genomic location, chromosome 13q31, correlates with loss of heterozygosity in several different cancers, including breast cancer (Eiriksdottir et al., 1998; Lin et al., 1999). The expression and function of miRNA varies by cell type. The miR-17/20 cluster functions as a tumor suppressor in the human B cell line P493-6 by decreasing E2F1 expression, thereby inhibiting myc-induced cell proliferation (O'Donnell et al., 2005). In contrast, in both lung cancer and lymphomas, expression of this miRNA cluster was increased, enhancing cell growth (Hayashita et al., 2005; He et al., 2005). As the same miRNA performs different functions through distinct pathways dependent on the tissue or cell type, it is important to understand the mechanisms by which miRNA regulates the cell cycle and thereby tumorigenesis.
###end p 7
###begin p 8
###xml 166 175 166 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 245 260 233 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Fu et al., 2004</xref>
###xml 276 285 264 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 343 352 331 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 352 355 340 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 463 466 451 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 470 475 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2</italic>
###xml 477 493 465 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">Lee et al., 2000</xref>
###xml 495 510 483 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Fu et al., 2004</xref>
###xml 559 562 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 567 570 555 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 572 592 560 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Johnson et al., 2005</xref>
###xml 594 616 582 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
The onset and progression of tumorigenesis involves evasion of apoptotic signals, sustained cellular proliferation, and the ability to promote tumor neoangiogenesis. Cyclin D1 overexpression is found in approximately50% of human breast cancers (Fu et al., 2004). Antisense to cyclin D1 abrogated the growth of ErbB2-induced breast tumors, and cyclin D1-/- mice are resistant to the induction of tumors either in the mammary gland or the skin induced by oncogenic ras or ErbB2 (Lee et al., 2000; Fu et al., 2004). A subset of miRNAs are regulated by oncogenic myc and ras (Johnson et al., 2005; O'Donnell et al., 2005), but the requirement for cell cycle proteins in the regulation of miRNA is still unknown. Furthermore, the understanding of the mechanism by which specific oncogenes regulate miRNA expression and function is limited.
###end p 8
###begin p 9
###xml 88 97 88 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 118 127 118 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 190 199 190 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 264 273 264 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 419 428 419 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 480 489 480 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 564 573 564 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 681 690 681 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 55 80 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 82 86 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 98 113 <span type="species:ncbi:10090">transgenic mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
By a large-scale miRnome analysis using miRNA chips on mouse mammary tumor virus (MMTV)-cyclin D1 transgenic mice and cyclin D1 knockout mice, we determined a subset of miRNAs controlled by cyclin D1. These studies identified a novel regulatory mechanism in which cyclin D1 induces a miRNA signature that includes miR-17-5p and miR-20a through the binding of the miR-17/20 promoter region. miR-17/20 in turn attenuates cyclin D1 abundance via a negative feedback loop to regulate cyclin D1 through a conserved 3' UTR miRNA binding site. Given the central role for cyclin D1 in cellular differentiation and tumorigenesis, the studies herein, which demonstrate that miRNAs determine cyclin D1 abundance, have broad implications for cancer biology. This work demonstrates additional regulatory mechanisms between oncogenes and tumor suppressor miRNAs that act in concert with other factors to limit oncogene function.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 25 34 25 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
miR-17/20 down-regulates cyclin D1 expression and suppresses breast cancer cell proliferation
###end title 11
###begin p 12
###xml 191 206 179 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">He et al., 2005</xref>
###xml 226 248 214 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Hayashita et al., 2005</xref>
The miR-17/20 cluster located on chromosome 13q31 encodes six miRNAs within an approximately1-kb region. Amplification and overexpression of miR-17/20 has been described in B cell lymphomas (He et al., 2005) and lung cancers (Hayashita et al., 2005). miR-17-5p and miR-20a are key important components of the miR-17/20 cluster. To characterize the miR-17/20 expression in breast cancer cell lines, Northern blot analysis was performed of nine breast cancer cell lines (MDA-MB-231, BT-474, MDA-MB-453, Hs578T, MDA-MB-486, SKBR-3, MDA-MB-361, MCF-7, and T-47D), one nontumorigenic breast epithelial cell line (MCF-10A), and two nonbreast tumor cell lines (HeLa and 293T; Fig. S1, available at ). The expression of miR-17-5p and miR-20a was low to undetectable in at least six of the nine breast cancer cell lines compared with either nontumorigenic breast epithelial cell (MCF-10A) or nonbreast cancer cell lines (HeLa and 293T). The reduced expression of miR-17/20 in breast cancer cells suggested the miRNA cluster may have a unique function during breast tumorigenesis.
###end p 12
###begin p 13
###xml 227 235 227 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 399 407 399 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 594 609 582 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, C and D</xref>
###xml 838 846 823 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 959 967 944 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 F</xref>
###xml 185 189 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 196 211 <span type="species:ncbi:10090">transgenic mice</span>
To further investigate the role of miR-17/20 in breast cancer, a retroviral vector encoding the miR-17/20 cluster was used to infect MCF-7 and the NAFA cell line, which is derived from MMTV-ErbB2 transgenic mice breast tumors (Fig. 1 A). Northern blotting confirmed the increased expression of the components in the miR-17/20 cluster (miR-17-5p, 18a, 19a, 19b, 20a, and 92) in the transduced cells (Fig. 1 B). Cellular proliferation assays were performed on the miR-17/20-transduced cells. miR-17/20 expression inhibited MCF-7 cell proliferation and cell growth by approximately60% after 72 h (Fig. 1, C and D). To determine if miR-17/20 regulated estrogen-dependent cellular proliferation, MCF-7 cells were treated with estrogen (17beta-estradiol). Both estrogen-dependent and -independent cell proliferation was inhibited by miR-17/20 (Fig. 1 E). Furthermore, miR-17/20 inhibited MCF-7 contact-independent growth determined through colony formation assays (Fig. 1 F).
###end p 13
###begin p 14
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">miR-17/20 inhibits breast cancer cell proliferation.</bold>
miR-17/20 inhibits breast cancer cell proliferation. (A) The genomic region of miR-17/20 cluster on chromosome 13q31 and the vector structure for miRNA17/20 overexpression. (B) Northern blot analysis demonstrating the increased expression of the six members of miR-17/20 cluster in the miR-17/20-transduced MCF-7 cells. tRNA served as loading control. (C and D) Cellular proliferation assay; (E) an MTT assay; and (F) a colony formation assay consistently showed the inhibition of MCF-7 cell proliferation by miR-17/20 overexpression. Cellular proliferation assays and the MTT assay were performed in three independent experiments (data are equal to mean +/- SEM). *, P < 0.01.
###end p 14
###begin title 15
###xml 41 42 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 54 63 54 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
miR-17/20 arrests the cell cycle at the G1 phase in a cyclin D1-dependent manner
###end title 15
###begin p 16
###xml 224 233 224 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 398 406 386 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
To determine the mechanism by which miR-17/20 suppressed breast cancer cell proliferation, the abundance of key cell cycle regulatory proteins was assessed. Cyclin D1 abundance is rate limiting for MCF-7 cell DNA synthesis. Cyclin D1 expression was inhibited approximately50% by miR-17/20 overexpression, whereas cyclin E, Cdk 4, and Cdk 6 expressions were unaltered in miR-17/20-transduced cells (Fig. 2 A).
###end p 16
###begin p 17
###xml 37 38 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">miR-17/20 arrests cell cycle at the G<sub>1</sub> phase in a cyclin D1&#8211;dependent manner.</bold>
###xml 111 120 111 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK4</italic>
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK6</italic>
###xml 138 146 138 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin E</italic>
###xml 189 192 189 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GDI</italic>
###xml 463 464 463 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 466 467 466 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 495 496 495 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
miR-17/20 arrests cell cycle at the G1 phase in a cyclin D1-dependent manner. (A) Western blot analysis of the cyclin D1, CDK4, CDK6, and cyclin E expression in miR-17/20-transduced cells. GDI served as loading control. (B) MCF-7 cells were transfected with cyclin D1 siRNA and control siRNA. Western blotting demonstrated the efficient knockdown of cyclin D1 after 72 h of siRNA treatment. (C) Cell cycle analysis indicated the increased population of cells at G0/G1 phase and decreased S and G2/M phase cells in miR-17/20-transduced MCF-7 cells under a cyclin D1 background. This difference was abolished by knockdown of cyclin D1 in cells. The analysis was performed in triplicates (data are equal to mean +/- SEM). (D) Northern blot demonstrated the increased expression of miR-17/20 in the miR-17/20-transduced NAFA cells. tRNA served as a loading control. (E) The MTT assay showed the inhibited cell proliferation of NAFA cells by miR-17/20 transduction. The assay was performed in three independent experiments, and the data are presented as the mean +/- SEM.
###end p 17
###begin p 18
###xml 77 86 77 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 149 157 149 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 497 498 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 647 655 639 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 663 664 655 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 666 667 658 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 901 902 889 890 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 979 980 967 968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 982 983 970 971 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1039 1040 1023 1024 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1042 1043 1026 1027 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1079 1087 1059 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
To examine the functional interrelationship between miR-17/20 and cyclin D1, cyclin D1 siRNA was used to transfect miR-17/20-transduced MCF-7 cells (Fig. 2 B). miR-17/20-transduced MCF-7 cells were starved with 5% charcoal-stripped serum for 48 h, and cellular DNA synthesis was stimulated by the addition of 10% normal FBS. Cell cycle analysis was conducted before serum stimulation and upon 16 h of serum treatment. The proportion of cells corresponding to the proportion of cells in the S and G2/M phase was lower in miR-17/20-transduced MCF-7 cells (25.9 +/- 0.6% vs. 9.9 +/- 0.3%) than that in control cells (31.1 +/- 0.4% vs. 14.9 +/- 0.8%; Fig. 2 C). The G0/G1 phase was increased in miR-17/20-transduced MCF-7 cells (62.4 +/- 0.6%) compared with control cells (51.8 +/- 0.1%). The inhibition of S phase by miR-17/20 was dependent on cyclin D1, as cyclin D1 knockdown with siRNA abrogated the G1 phase and S phase differences between miR-17/20 overexpressed MCF-7 cells (G0/G1: 67.5% +/- 0.7%; S, 14.8 +/- 1.0%) and control cells (G0/G1: 68.8% +/- 0.5%; S, 14.4 +/- 0.6%; Fig. 2 C).
###end p 18
###begin p 19
###xml 151 157 151 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 321 322 321 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
MCF-7 cells express abundant cyclin D1. In contrast with MCF-7 cells, transduction of MCF-10A and BT-474 cells, which have low abundance of cyclin D1 (Fig. 3), with the miR-17/20 cluster had no demonstratable effect on DNA synthesis induced by FBS (Fig. S2, available at ). These results indicate that the inhibition of G1/S transition by miR-17/20 is cyclin D1 dependent.
###end p 19
###begin p 20
###xml 32 41 32 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 0 123 0 123 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The inverse correlation between <italic>cyclin D1</italic> abundance and miR-17/20 expression in human breast cancer tissues and cell lines.</bold>
###xml 167 176 167 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 275 284 275 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 524 533 521 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 602 611 599 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 731 740 728 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 769 774 <span type="species:ncbi:9606">human</span>
The inverse correlation between cyclin D1 abundance and miR-17/20 expression in human breast cancer tissues and cell lines. (A) Western blots showed the repression of cyclin D1 and AIB1 abundance by miR-17/20. Both anti-miR-17-5p and anti-miR-20a increased the expression of cyclin D1 and AIB1 in cells. AIB1 is a positive control. beta-tubulin was a loading control. (B) Cotransfection of anti-miR-17-5p or anti-miR-20a reversed the antiproliferative function of miR-17/20 in MCF-7 cells. (C) Western blots showed the high cyclin D1 level in low miR-17/20-expressing breast cancer cell lines, and low cyclin D1 in high miR-17/20 cell lines. A Northern blot of miRNA17/20 is shown in Fig. S1 (available at ). (D) The abundances of cyclin D1 and miR-17-5p/miR-20a in 16 human breast tumor tissues and 16 matching normal breast tissues were determined by Western and Northern blots. Tissue sample IDs were provided by the sample provider. Black lines indicate that intervening lanes have been spliced out. N, normal tissue; T, tumor tissue. (E) Statistically significant down-regulation of miR-17/20 expression in breast tumors over matching normal tissue. P = 0.004 by Wilcoxon signed rank test. The grayscale intensity of each band in D was obtained by AlphaImager software. The y axis value stands for the addition of miR-17-5p and miR-20a expression in each sample. (F) Significant up-regulation of cyclin D1 expression in breast tumors over matching normal tissue. P = 0.001. (G) Plotting the paired difference of tumor and normal samples expression for each marker (miR-17/20 vs. cyclin D1). The exact McNemar's test indicates a significant association between the up-regulation of expression in cyclin D1 and the down-regulation of miR-17/20 expression. P = 0.002.
###end p 20
###begin p 21
###xml 427 435 415 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 544 552 532 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 D</xref>
###xml 615 623 603 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 178 193 <span type="species:ncbi:10090">transgenic mice</span>
###xml 230 234 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
The ErbB2 oncogene is overexpressed or amplified in approximately30% of human breast cancers and is sufficient for mammary tumor generation when targeted to the mammary gland in transgenic mice. The NAFA cell line is derived from MMTV-ErbB2 transgenic tumors. To determine the role of miR-17/20 cluster in ErbB2-mediated tumor growth, the NAFA cell line was transduced with the expression vector encoding an miR-17/20 cluster (Fig. 1 A). The expression of miR-17-5p and miR-20a was induced in NAFA cells transduced with the miRNA17/20 cluster (Fig. 2 D). miR-17/20 expression inhibited proliferation of NAFA cells (Fig. 2 E).
###end p 21
###begin p 22
###xml 65 74 65 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 523 532 523 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 557 565 557 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 637 645 637 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 724 728 724 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 816 836 816 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Hossain et al., 2006</xref>
###xml 862 871 862 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 876 880 876 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 953 961 953 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
To examine further the specificity with which miR-17/20 inhibits cyclin D1 abundance, chemically modified miRNA inhibitors (anti-mir) were used to block miRNA function. The miR-17/20 locus-transduced MCF-7 cells were transfected with anti-miR-17-5p and anti-miR-20a, which can specifically interact with miR-17-5p and miR-20a, respectively, to block their function. Cyclin D1 abundance is rate-limiting in MCF-7 cells for DNA synthesis and cell proliferation. Both anti-miR-17-5p and anti-miR-20a rescued the inhibition of cyclin D1 abundance by miR-17/20 (Fig. 3 A). Both anti-mirs reversed the antiproliferative function of miR-17/20 (Fig. 3 B), which is consistent with the functional role of cyclin D1. The abundance of AIB1, a target of miR-17-5p repression, was inhibited as previously described by miR-17/20 (Hossain et al., 2006). The down-regulation of cyclin D1 and AIB1 by miR-17/20 could be rescued by either anti-miR-17-5p or anti-miR-20a (Fig. 3 A).
###end p 22
###begin p 23
###xml 52 61 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
To determine whether endogenous miR-17/20 regulates cyclin D1 abundance and cell proliferation, MCF-7 cells were transfected with anti-miR-17-5p and anti-miR-20a. Inhibition of these endogenous miRNAs' function enhanced cellular proliferation and cyclin D1 abundance (Fig. S3, available at ).
###end p 23
###begin p 24
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 102 117 102 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Fu et al., 2004</xref>
###xml 148 157 148 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 239 248 239 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 370 379 370 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 435 450 435 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, C and D</xref>
###xml 579 587 579 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 623 632 623 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 690 698 690 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 F</xref>
###xml 838 846 838 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 G</xref>
###xml 279 284 <span type="species:ncbi:9606">human</span>
###xml 331 336 <span type="species:ncbi:9606">human</span>
Cyclin D1 is rate-limiting in tumorigenesis induced by several breast oncogenes (Ras, Src, and ErbB2; Fu et al., 2004). In view of the finding that cyclin D1 level was reduced by miR-17/20 expression, we examined the relative abundance of cyclin D1 and miR-17/20 in 11 different human cell lines and 16 matched normal and tumorous human breast samples. The abundance of cyclin D1 and expression of miR-17/20 were inversely correlated (Fig. 3, C and D). Statistical analysis showed significant down-regulation of miR-17/20 expression in breast tumors over matching normal tissue (Fig. 3 E), and significant up-regulation of cyclin D1 expression in breast tumors over matching normal tissue (Fig. 3 F). There is a significant association between the up-regulation of expression in cyclin D1 and the down-regulation of miR-17/20 expression (Fig. 3 G)
###end p 24
###begin title 25
miR-17/20 represses cyclin D1 through a conserved 3' UTR binding site
###end title 25
###begin p 26
###xml 56 65 56 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 246 254 246 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 315 324 315 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 408 417 408 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 478 486 478 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 551 560 551 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 596 604 596 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 657 666 657 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 668 677 668 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 747 755 747 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 D</xref>
###xml 774 783 774 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 908 916 908 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 D</xref>
###xml 1218 1226 1218 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 E</xref>
###xml 1262 1271 1262 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1492 1500 1492 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 E</xref>
###xml 392 397 <span type="species:ncbi:9606">human</span>
###xml 402 407 <span type="species:ncbi:10090">mouse</span>
###xml 545 550 <span type="species:ncbi:9606">human</span>
To determine the mechanism by which miR-17/20 inhibited cyclin D1 abundance, quantitative real-time PCR analysis was conducted. No significant difference in cyclin D1 mRNA levels was observed between miR-17/20-transduced cells and control cells (Fig. 4 A). This result suggests that the miR-17/20 cluster regulates cyclin D1 gene expression at the posttranscriptional level. Alignment of the human and mouse cyclin D1 mRNA 3' UTRs identified a conserved miR-17/20-binding site (Fig. 4 B). The miR-17/20-binding site (nucleotides 2,109-2,117) of human cyclin D1 is well conserved between species (Fig. 4 C). To determine whether miR-17/20 directly regulates cyclin D1, cyclin D1 mRNA 3' UTR was linked to the firefly luciferase as a reporter gene (Fig. 4 D). Full-length and cyclin D1 3' UTR fragments containing a wild-type or mutant miR-17/20-binding site were inserted into the luciferase reporter vector (Fig. 4 D). A construct without the miRNA binding sites was used as a negative control. When introduced into MCF-7 cells, the full-length cyclin D1 3' UTR reporter showed a 90% reduction in luciferase activity in the miR-17/20-transduced cells compared with empty luciferase vector and negative control vector (Fig. 4 E). The reporter vector carrying the cyclin D1 3' UTR fragment with the miR-17/20 binding site showed reduced luciferase activity in the transduced cells compared with control cells. Mutation of the miR-17/20 binding site abrogated repression of luciferase activity (Fig. 4 E).
###end p 26
###begin p 27
###xml 20 29 20 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">miR-17/20 represses <italic>cyclin D1</italic> expression through a conserved 3&#8242; UTR site.</bold>
###xml 167 176 167 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 431 440 429 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 614 623 612 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1024 1033 1022 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1137 1146 1135 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1332 1341 1330 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1765 1766 1758 1759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 425 430 <span type="species:ncbi:10090">mouse</span>
###xml 710 715 <span type="species:ncbi:9606">human</span>
###xml 717 722 <span type="species:ncbi:10090">mouse</span>
###xml 724 727 <span type="species:ncbi:10116">rat</span>
###xml 733 736 <span type="species:ncbi:9615">dog</span>
miR-17/20 represses cyclin D1 expression through a conserved 3' UTR site. (A) Quantitative real-time RT-PCR assay did not show significant difference in mRNA level of cyclin D1 between miR-17/20-transduced cells and control cells. ABI1 was a positive control. 18S served as an internal control for normalization. This experiment was repeated three times in triplicate. Data are mean +/- SEM. (B) BLASTN analysis of human and mouse cyclin D1 mRNAs identified a miR-17-5p- and miR-20a-binding site at the conserved 3' UTR region. (C) Sequence alignment of the miR-17-5p and miR-20a base-paring site in the 3' UTR of cyclin D1 mRNAs. The region complementary to the 2-10 nt of miR-17/20 is highly conserved among human, mouse, rat, and dog. The "seed" sequence of miR-17/20 that is complementary to cyclin D1 is shown in italics and boxed. The mutant sequence is identical to the wild-type sequence except the mutated nucleotides are shown in red. (D) Luciferase reporter assay constructs. 3' UTR FL, the full-length 3' UTR of cyclin D1 inserted to the downstream of the luciferase coding region in the pGL3 vector; 3' UTR-1, a fragment of cyclin D1 3' UTR containing the miR-17/20-binding sequence; 3' UTR-1-mu, the mutated construct identical to 3'UTR-1 but point mutated in the miR-17/20 binding site; 3' UTR-2, another fragment of cyclin D1 3' UTR without the miR-17/20-binding sequence. (E) Luciferase reporter assay showed the decreased luciferase activity in miR-17/20 overexpressed cells for both 3' UTR FL and 3' UTR-1 constructs, but not for the PGL-3 empty vector, 3'UTR-1-mu and 3'UTR-2 constructs. The luciferase activity was normalized to beta-galactosidase. Data are derived from three independent experiments. Values are presented as the mean +/- SEM (n = 3). *, P < 0.01
###end p 27
###begin title 28
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
Cyclin D1 is required for induction of miR-17/20 expression
###end title 28
###begin p 29
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1</italic>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1</italic>
###xml 104 126 104 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 128 150 128 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Sylvestre et al., 2007</xref>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F</italic>
###xml 165 174 165 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 180 183 180 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pRb</italic>
###xml 213 214 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 216 217 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 304 305 304 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 349 351 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1.</sub>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 364 373 364 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 401 402 401 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 486 495 486 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 574 583 574 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 620 629 620 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 629 632 629 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 689 698 689 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 746 755 746 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 888 896 888 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 958 967 958 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 967 970 967 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 978 986 978 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1015 1024 1015 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1024 1027 1024 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1126 1134 1126 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1228 1231 1228 1231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1260 1268 1260 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 633 638 <span type="species:ncbi:10090">mouse</span>
miR-17/20 can be induced by c-myc or E2F1, and miR-17/20 in turn negatively regulates E2F1 translation (O'Donnell et al., 2005; Sylvestre et al., 2007). c-myc, E2F, cyclin D1, and pRb are important regulators of G0/G1-S transition of the cell cycle. The miR-17/20 cluster is activated by c-myc in early G1, and the E2F1 protein accumulates in late G1. Like c-myc, cyclin D1 is activated early in the G1 phase. As c-myc is capable of inducing miR-17/20, we examined the possibility that cyclin D1 may also induce miR-17/20 expression. A retroviral expression vector encoding cyclin D1 was used to transduce wild-type and cyclin D1-/- mouse embryonic fibroblasts (MEFs) to determine whether cyclin D1 was sufficient to induce miR-17/20 expression. Cyclin D1 overexpression was confirmed by Western blotting (Fig. S4, available at ), and miRNA expression was confirmed by Northern blotting (Fig. 5 A). miR-17-5p expression was reduced to undetectable levels in cyclin D1-/- cells (Fig. 5 A). Cyclin D1 transduction of cyclin D1-/- cells resulted in physiological levels of cyclin D1 and induced miR-17-5p and miR-20a expression (Fig. 5 A, lanes 3 vs. 4). An unrelated miRNA, miR-100, showed no difference in expression in cyclin D1-/- cells by Northern blotting (Fig. 5 A) and miRNA chip analysis (not depicted).
###end p 29
###begin p 30
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Cyclin D1</italic> induces miR-17-5p and miR-20a expression.</bold>
###xml 284 293 284 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 293 296 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 302 311 302 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 311 314 311 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 658 667 658 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 667 670 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 693 702 693 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 702 705 702 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 760 769 760 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 804 805 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 755 759 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
Cyclin D1 induces miR-17-5p and miR-20a expression. (A) Northern blotting showed the increased expression of miR-17-5p and miR-20a in the MSCV-cyclin D1-infected MEF cells. miR-100 was used as a negative control. tRNA served as loading control. (B) Breast cancer cell line MCF-7. (C) cyclin D1-/-, and cyclin D1+/+ MEFs were starved by 5% charcoal-stripped serum for 48 h, followed by 10% FBS stimulation. The time course examination of the cyclin D1 protein level and the miR-17-5p expression level were performed by Western and Northern blots, respectively. The results showed the induction of cyclin D1 and miR-17-5p by serum stimulation in the MCF-7 and cyclin D1+/+ MEF cells, but not in cyclin D1-/- MEFs. (D) miR-17-5p and miR-20a detection in the MMTV-cyclin D1 transgene induced mammary tumors (n = 3) compared with normal mice mammary gland. Data from three mammary tumor samples were presented as mean +/- SEM. (E) Real-time PCR analysis of cyclin D1 chromatin immunoprecipitated DNA. 11 fragments derived from chromosome 11q31 upstream of miR-17/20 cluster were examined. For each fragment, amplifications on chromatin before immunoprecipitation and chromatin immunoprecipitated with preimmune serum were performed as input and negative control, respectively. This experiment was repeated three times; data are equal to mean +/- SEM.
###end p 30
###begin p 31
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 184 193 184 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 288 296 288 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 299 308 299 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 420 428 420 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 452 461 452 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 548 557 548 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 557 560 557 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 565 574 565 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 574 577 574 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 638 647 638 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 647 650 647 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 659 668 659 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 668 671 668 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 678 686 678 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 705 714 705 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 747 756 747 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 803 812 803 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1016 1025 1016 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1050 1058 1050 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 742 746 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 757 772 <span type="species:ncbi:10090">transgenic mice</span>
###xml 798 802 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 848 853 <span type="species:ncbi:10090">mouse</span>
To determine whether miR-17-5p and cyclin D1 are coordinately regulated by physiological stimulation, MCF-7 cells were serum-starved and then stimulated by 10% FBS. The time course of cyclin D1 expression and miR-17-5p induction were detected by Western and Northern blots, respectively (Fig. 5 B). Cyclin D1 protein abundance was increased at 6 h, with maximal abundance at 12 h. miR-17-5p expression increased at 6 h (Fig. 5 B). To determine whether cyclin D1 was required for serum-mediated induction of miR-17-5p, a comparison was made between cyclin D1-/- and cyclin D1+/+ MEFs. The induction of miR-17-5p by serum was identified in cyclin D1+/+ but not cyclin D1-/- MEFs (Fig. 5 C). To determine if cyclin D1 induced miR-17/20 in vivo, MMTV-cyclin D1 transgenic mice were assessed. RNAs from MMTV-cyclin D1-induced mammary tumors, and normal mouse mammary gland were compared and analyzed for miRNA expression using miRNA chips. Consistent with the in vitro data, the miR-17/20 cluster was up-regulated in the cyclin D1-induced mammary tumors (Fig. 5 D).
###end p 31
###begin title 32
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
Cyclin D1 binds the promoter of the miR-17/20 cluster
###end title 32
###begin p 33
###xml 44 53 44 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 240 257 240 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Wang et al., 2003</xref>
###xml 259 277 259 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Hulit et al., 2004</xref>
###xml 279 294 279 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Fu et al., 2005</xref>
###xml 370 379 370 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 393 402 393 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">miR-17/20</italic>
###xml 586 595 586 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 847 855 847 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
###xml 876 885 876 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 938 946 938 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
###xml 1133 1142 1133 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 449 454 <span type="species:ncbi:9606">human</span>
Cyclin D1 induced miR-17/20 expression, and cyclin D1 is known to regulate gene transcription through occupancy of a subset of gene promoters in the context of local chromatin, thereby regulating cellular differentiation and proliferation (Wang et al., 2003; Hulit et al., 2004; Fu et al., 2005). Chromatin immunoprecipitation assays were performed to determine whether cyclin D1 occupied the miR-17/20 promoter in the context of local chromatin in human breast epithelial cells. MCF-10A cells were fixed, and a cell lysate was prepared. Using a cyclin D1 antibody to immunoprecipitate cyclin D1-binding DNAs, preimmune serum was used as negative control. DNA was amplified by real-time PCR. 3 kb of the miR-17/20 cluster upstream region was examined by 11 different pairs of primers, which divide the miR-17/20 promoter region into 11 fragments (Fig. 5 E, fragments 1-11). A cyclin D1-specific binding site was identified at fragment 5 (Fig. 5 E). Sequence analysis of this 139-bp fragment identified multiple GC boxes upstream of fragment 5 and two TATA boxes downstream of fragment 5. Collectively, these studies demonstrate that cyclin D1 binds to the miR-17/20 promoter and induces miR-17/20 expression at the transcriptional level.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 111 129 111 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">Calin et al., 2004</xref>
###xml 131 152 131 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Calin and Croce, 2006</xref>
###xml 154 186 154 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Esquela-Kerscher and Slack, 2006</xref>
###xml 188 206 188 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Zhang et al., 2007</xref>
###xml 428 449 428 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Croce and Calin, 2005</xref>
###xml 649 664 649 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">He et al., 2005</xref>
###xml 666 688 666 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 690 710 690 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Hossain et al., 2006</xref>
###xml 823 826 823 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Myc</italic>
###xml 847 862 847 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">He et al., 2005</xref>
###xml 949 971 949 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 1056 1065 1056 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
Several independent lines of evidence implicate miRNAs as either tumor suppressors or collaborative oncogenes (Calin et al., 2004; Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006; Zhang et al., 2007). miRNAs are differentially expressed in tumors, specific miRNAs are located within regions of chromosomal deletions or rearrangements in tumors, and miRNAs can cooperate with oncogenes in tumorigenesis in animal models (Croce and Calin, 2005). Importantly, the function of individual miRNAs may be cell-type specific. The miR-17/20 cluster has been found to function either as onco-miRNA or as a tumor-suppressor depending on the cell type (He et al., 2005; O'Donnell et al., 2005; Hossain et al., 2006). Expression of the miR-17/20 cluster was increased by 65% in B cell lymphomas, and miR-17/20 cooperates with c-Myc in lymphomagenesis (He et al., 2005). In contrast, the miR-17/20 cluster inhibited proliferation of the P493-6 cell line (O'Donnell et al., 2005). Herein, miR-17/20 inhibited breast cancer cellular proliferation by repression of cyclin D1 translation.
###end p 35
###begin p 36
###xml 146 155 146 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 211 212 211 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 254 269 254 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Fu et al., 2004</xref>
###xml 396 417 396 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Albanese et al., 1995</xref>
###xml 419 434 419 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Fu et al., 2004</xref>
###xml 508 524 508 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">Lee et al., 2000</xref>
###xml 526 541 526 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">Yu et al., 2001</xref>
###xml 934 955 934 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Tavazoie et al., 2008</xref>
###xml 1001 1022 1001 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Tavazoie et al., 2008</xref>
###xml 1148 1152 1148 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD44</italic>
###xml 1154 1172 1154 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">Huang et al., 2008</xref>
###xml 1274 1275 1274 1275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1474 1475 1474 1475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1505 1514 1505 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1541 1542 1541 1542 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1630 1639 1630 1639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1682 1683 1682 1683 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1705 1720 1705 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">Fu et al., 2004</xref>
###xml 1741 1750 1741 1750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 620 625 <span type="species:ncbi:9606">human</span>
###xml 685 700 <span type="species:ncbi:10090">transgenic mice</span>
Our findings are of importance to the understanding of breast tumorigenesis, as they directly link the miR-17/20 cluster to the regulation of the cyclin D1 gene. Cyclin D1 plays a key role in regulation of the G1-S phase transition and in tumorigenesis (Fu et al., 2004). The abundance of cyclin D1 is induced by a broad array of oncogenic stimuli and is required for contact-independent growth (Albanese et al., 1995; Fu et al., 2004). Cyclin D1 is required for ErbB2-induced mammary tumorigenesis in vivo (Lee et al., 2000; Yu et al., 2001). Herein, an inverse correlation was found between miR-17/20 and cyclin D1 in human breast cancer samples, in breast cancer cell lines, and in transgenic mice. Our finding that miRNA regulate breast cancer cellular proliferation and contact-independent growth is consistent with recent findings that specific miRNA can regulate breast cancer progression. miR-126 reduces breast tumor growth (Tavazoie et al., 2008), miR-335 inhibits breast cancer metastasis (Tavazoie et al., 2008), and miR-373 and miR-520c stimulate breast cancer cell migration and invasion by suppressing the metastasis suppressor gene CD44 (Huang et al., 2008). The current studies provide evidence for an additional level of fine control in regulation of the G1-S phase transition of the cell cycle. The inhibition of DNA synthesis by miR-17/20 was associated with a reduction in the proportion of cells in the S phase and an increased proportion of cells in G1 phase. Cyclin E, which, like cyclin D1, is capable of enhancing G1-S phase transition in MCF-7 cells, was not regulated by miR-17/20. As the abundance of cyclin D1 is rate-limiting in MCF7 cell growth and G1-S phase progression (Fu et al., 2004), the inhibition of cyclin D1 expression by miR-17/20 likely contributes to the inhibition of DNA synthesis and cellular proliferation in breast cancer cells.
###end p 36
###begin p 37
###xml 5 14 5 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 92 93 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 114 123 114 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1</italic>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 224 246 224 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Matsumura et al., 2003</xref>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1</italic>
###xml 323 345 323 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1</italic>
###xml 530 539 530 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 548 551 548 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F</italic>
###xml 565 574 565 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 647 656 635 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 883 892 871 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 966 975 954 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1086 1095 1074 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 1171 1180 1159 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 621 626 <span type="species:ncbi:9606">human</span>
Both cyclin D1 and c-myc are activated early in the G1 phase and are key regulators of the G1-S phase transition. Cyclin D1 activates E2F1 transactivation through phosphorylation of pRb. E2F1 expression is induced by c-myc (Matsumura et al., 2003). miR-17-5p and miR-20a limit c-myc-mediated induction of E2F1 translation (O'Donnell et al., 2005), providing a mechanism to dampen reciprocal activation of c-myc to E2F1. Our studies provide evidence for a novel level of fine tuning to regulate the functional interactions between cyclin D1, c-myc, E2F, and miRNAs. Cyclin D1 abundance is increased in approximately50% of human breast cancers. The cyclin D1 gene encodes the labile catalytic subunit of the holoenzyme that phosphorylates and inactivates the pRb protein. The pRb protein serves as a paradigmatic tumor suppressor. The current studies are the first to demonstrate that cyclin D1 abundance is controlled by miRNA. The binding site identified within the cyclin D1 3' UTR required for repression by miR-17/20 is highly conserved between species. As the relative abundance of cyclin D1 is tightly regulated, multiple distinct mechanisms are involved to control cyclin D1 abundance, including transcriptional induction, posttranslational regulation, and in the current studies, posttranscriptional regulation via miRNA.
###end p 37
###begin p 38
###xml 49 58 49 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 148 157 148 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 265 274 265 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 370 379 370 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 568 583 564 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Fu et al., 2005</xref>
###xml 585 602 581 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Wang et al., 2003</xref>
###xml 613 622 609 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
The studies herein provide genetic evidence that cyclin D1 binds to an miRNA promoter and regulates a specific miRNA signature. Genetic knockout of cyclin D1 or siRNA treatment demonstrated that the miR-17/20 cluster is induced by cyclin D1. Mammary gland-targeted cyclin D1 expression recapitulated this miRNA signature in the mammary gland tumor. In previous studies, cyclin D1 was identified within chromatin of target endogenous gene promoters in the context of nuclear receptor binding sites (peroxisome proliferator-activated receptor gamma) and AP-1/CRE sites (Fu et al., 2005; Wang et al., 2003). Herein, cyclin D1 was identified within the miR-17/20 promoter in the context of local chromatin using chromatin immunoprecipitation assays, extending the potential mechanisms by which cyclin D1 may regulate other miRNAs.
###end p 38
###begin p 39
###xml 80 102 80 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 104 126 104 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Sylvestre et al., 2007</xref>
###xml 182 204 182 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 206 228 206 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Sylvestre et al., 2007</xref>
###xml 426 448 426 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 450 470 450 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">Fontana et al., 2007</xref>
###xml 472 494 472 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Sylvestre et al., 2007</xref>
###xml 608 614 608 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 722 742 722 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Hossain et al., 2006</xref>
Previous studies have demonstrated the induction of miR-17/20 by c-myc and E2F (O'Donnell et al., 2005; Sylvestre et al., 2007). The E2F family is negatively regulated by miR-17/20 (O'Donnell et al., 2005; Sylvestre et al., 2007). We examined the abundance of c-myc in miR-17/20-overexpressed cells and found the repression of c-myc by miR-17-5p (Fig. S5, available at ). Thus, four key regulatory proteins-c-Myc, E2F1, AML1 (O'Donnell et al., 2005; Fontana et al., 2007; Sylvestre et al., 2007), and cyclin D1-converge on the miR-17/20 cluster promoter region to create important regulatory feedback loops (Fig. 6). Consistent with this model, translation of the cyclin D1-binding protein AIB1 is repressed by miR-17/20 (Hossain et al., 2006). In turn, miR-17-15p/miR-20a attenuates this activity by inhibiting each of these upstream activators. These attenuating feedback loops provide mechanisms to tightly control proliferative signals. Herein, the expression of miR-17/20 was increased by cyclin D1 in mammary gland-targeted cyclin D1 transgene-induced breast tumors. Thus, the phenotype of cellular growth may be determined by the ability of cyclin D1 to evade translational attenuation by miR-17/20.
###end p 39
###begin p 40
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">miR-17/20 regulatory loops.</bold>
miR-17/20 regulatory loops. (A) E2F-miR-17/20 regulatory loop. (B) AML1-miR-17/20 regulatory loop. (C) c-Myc-miR-17/20 regulatory loop. (D) cyclin D1-miR-17/20 regulatory loop. Red arrows are supported by our data. Black arrows are supported by scientific literature.
###end p 40
###begin title 41
Materials and methods
###end title 41
###begin title 42
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 9 14 <span type="species:ncbi:9606">human</span>
Mice and human breast samples
###end title 42
###begin p 43
###xml 142 151 142 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 151 154 151 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 241 259 241 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Hulit et al., 2004</xref>
###xml 326 344 326 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Hulit et al., 2004</xref>
###xml 347 356 347 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 423 440 423 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">Wang et al., 1994</xref>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 357 372 <span type="species:ncbi:10090">transgenic mice</span>
###xml 443 447 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 458 473 <span type="species:ncbi:10090">transgenic mice</span>
###xml 548 553 <span type="species:ncbi:9606">Human</span>
All animal experiments were done in accordance with the guidelines for the care and use of laboratory animals at Thomas Jefferson University. Cyclin D1-/- mice were maintained on a mixed C57B1/6 x 129/SvJ background as described previously (Hulit et al., 2004). Genotyping was done on tail DNA by PCR as described previously (Hulit et al., 2004). Cyclin D1 transgenic mice were made and maintained as described previously (Wang et al., 1994). MMTV-cyclin D1 transgenic mice were obtained from A. Arnold (University of Connecticut, Farmington, CT). Human breast cancer specimens and matching normal breast tissue samples were provided by P. McCue (Thomas Jefferson Hospital, Philadelphia, PA). All the procedures were approved by the Institutional Review Board of Thomas Jefferson University. Expression for miR-17/20 and cyclin D1 in paired tumor and normal samples were analyzed for significant up- or down-regulation using the Wilcoxon signed rank test. The association of down-regulation in miRNA expression and up-regulation in cyclin D1 expression was completed via the exact McNemar's test. AlphaImager (Alpha Innotech) was used for intensity analysis.
###end p 43
###begin title 44
Vectors
###end title 44
###begin p 45
###xml 195 204 195 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 381 390 381 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 540 544 540 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">puro</sub>
###xml 633 655 633 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">O'Donnell et al., 2005</xref>
###xml 189 194 <span type="species:ncbi:9606">Human</span>
###xml 232 237 <span type="species:ncbi:10090">mouse</span>
###xml 745 748 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
miR-17/20 expression vector was provided by J. Mendell (Johns Hopkins University School of Medicine, Baltimore, MD) and A. Thomas-Tikhonenko (University of Pennsylvania, Philadelphia, PA). Human cyclin D1 cDNAs were cloned into the mouse stem cell virus (MSCV)-internal ribosome entry site (IRES)-GFP retrovirus vector at the EcoRI site. Different lengths of wild-type and mutated cyclin D1 3' UTR sequences were inserted into the XbaI-FseI site immediately downstream of the stop codon in the pGL3 firefly luciferase reporter vector. pMSCVpuro vector was used to express miR-17/20 cluster at the EcoRI site as described previously (O'Donnell et al., 2005). A recombinant plasmid that carries the bacterial beta-galactosidase cDNA driven by the CMV promoter was used as an internal control for transfection efficiency.
###end p 45
###begin title 46
Oligonucleotides
###end title 46
###begin p 47
All DNA probes were synthesized by Integrated DNA Technologies. Primer sequences for cyclin D1 3' UTR cloning were as follows: 3' UTR FL forward, 5'-GGGCGCCAGGCAG-3'; 3' UTR FL reverse, 5'-ACAGGACAGACT-3'; 3' UTR-1 forward, 5'-ACCATCCAGTGGAGG-3'; 3' UTR-1 reverse, 5'-TGGCAATGTGAGAAT-3'; 3' UTR-2 forward, 5'-GCCGCAGCTCCATT-3'; and 3' UTR-2 reverse, 5'-ATGGCTAAGAGAA-3'. The probe sequences for miRNA northern analysis were as follows: miR-17-5p, 5-ACTACCTGCACTGTAAGCACTTTG-3'; miR-18a, 5'-TATCTGCACTAGATGCACCTTA-3'; miR-19a, 5'-TCAGTTTTGCATAGATTTGCACA-3'; miR-19b, 5'-TCAGTTTTGCATGGATTTGCACA-3'; miR-20a, 5'-CTACCTGCACTATAAAGCACTTTA-3'; miR-92, 5'-ACAGGCCGGGGACAAGTGCAATA-3', and miR-100, 5'- CACAAGTTCGGATCTACGGGTT-3'. siRNAs were obtained from QIAGEN. Target sequence for cyclin D1: 5'-AACAAGCTCAAGTGGAACCTG-3'; target sequence for negative control siRNA: 5'-AATTCTCCGAACGTGTCACGT-3'. Anti-miR miRNA inhibitors are chemically modified, single-stranded nucleic acids antisense to target miRNAs. Anti-miR-17, anti-miR-20, and negative controls were obtained from Ambion.
###end p 47
###begin title 48
Cell culture
###end title 48
###begin p 49
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyclin D1</italic>
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 17 26 17 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 82 99 82 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Wang et al., 2003</xref>
###xml 162 167 <span type="species:ncbi:9796">horse</span>
###xml 444 448 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 454 459 <span type="species:ncbi:10090">mouse</span>
Cyclin D1+/+ and cyclin D1-/- primary MEFs were prepared as described previously (Wang et al., 2003). MCF-10A cells were cultured in DME/F12 medium containing 5% horse serum, 10 mug/ml insulin, 20 ng/ml EGF, 100 ng/ml choleratoxin, 0.5 mug/ml hydrocortisone, and 100 mg/liter of penicillin and streptomycin. 293T, Hela, MCF-7, Hs578T, T47D, BT474, SKBR-3, MDA-MB-231, MDA-MB-361, MDA-MB-453, MDA-MB-486, and the NAFA cell line derived from the MMTV-NeuT mouse cells were cultured in DME containing penicillin and streptomycin (100 mg of each per liter) and supplemented with 10% FBS.
###end p 49
###begin title 50
Retrovirus infection, siRNA/plasmid transfection, and luciferase reporter assay
###end title 50
###begin p 51
###xml 86 101 86 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Li et al., 2006</xref>
###xml 363 364 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 523 526 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Retroviral production and infection methods have been described previously in detail (Li et al., 2006). The ecotropic packaging vector pSV-Psi-E-MLV, which provides ecotropic packaging helper function, was used with retrovirus to infect cells. For cellular transfection with plasmid DNA, actively growing cells were seeded on 12-well plates at a density of 1 x 105 cells per well in an antibiotic-free medium. The next day, cells were cotransfected using Lipofectamine 2000 (Invitrogen) with 0.5 mug of pGL3 and 0.1 mug of CMV/beta-galactosidase plasmid. 24 h after transfection, luciferase activities were measured by AutoLumat (Berthold Technologies) and normalized with beta- galactosidase. For the reverse transfection of siRNA to MCF-7 cells, Lipofectamine RNAiMAX was used according to the manufacturer's instructions (Invitrogen).
###end p 51
###begin title 52
miRNA expression profiling and data analysis
###end title 52
###begin p 53
###xml 142 158 142 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Liu et al., 2004</xref>
###xml 395 400 <span type="species:ncbi:9606">human</span>
###xml 405 410 <span type="species:ncbi:10090">mouse</span>
miRNA expression arrays were generated at Kimmel Cancer Center at Thomas Jefferson University and probed essentially as described previously (Liu et al., 2004). In brief, 5 mug of total RNA from each sample was biotin-labeled during reverse transcription using random hexanes. Hybridization was performed on an miRNA microarray chip that contained 368 probes in triplicate, corresponding to 245 human and mouse miRNA genes. All probes on these microarrays were 40-mer oligonucleotides spotted by contacting technologies and covalently attached to a polymeric matrix. Hybridization signals were detected by biotin binding of a Streptavidin-Alexa 647 conjugate using a ScanArray XL5K (PerkinElmer). Scanner images were quantified by the Quantarray software (PerkinElmer). Signal intensities were normalized and analyzed using GeneSpring software (Agilent Technologies).
###end p 53
###begin title 54
miRNA Northern blot analysis
###end title 54
###begin p 55
###xml 72 87 72 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">Yu et al., 2005</xref>
###xml 447 449 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Northern blot analysis of miRNAs was performed as described previously (Yu et al., 2005). In brief, total RNA (10-20 mug per lane) was loaded on a 15% denaturing polyacrylamide gel and electophoresed at 200 V until the bromophenol blue approached the bottom. The RNA was transferred from the gel to Hybond-N+ membrane using a semidry transfer apparatus (Bio-Rad Laboratories). DNA oligonucleotide probes (20-23 nt) were 5'-end labeled with [gamma-32P]ATP, and hybridization was performed using Rapid-Hyb buffer according to the manufacturer's instructions (GE Healthcare).
###end p 55
###begin title 56
Real time RT-PCR analysis
###end title 56
###begin p 57
Total RNA was extracted with Trizol reagent (Invitrogen). The 7900 HT Sequence Detection System (Applied Biosystems) was used for quantitative RT-PCR assay. Primers were designed using primer Express 1.5/Taqman Primer Design software (Applied Biosystems). The primer sequences were as follows: cyclin D1 forward, 5'-AAGCTGTGCATCTACACCGA-3'; cyclin D1 reverse, 5'-CTTGAGCTTGTTCACCAGGA-3'; AIB-1 forward, 5'-AAACTCCATGGGAAGACCAG-3'; AIB-1 reverse, 5'-GTCTCGCACCTGGTATGCTA-3'; 18S forward, 5'-CTACCACATCCAAGGAAGGCA-3'; and 18S reverse, 5'-TTTTTCGTCACTACCTCCCCG-3'.
###end p 57
###begin title 58
Western blot analysis
###end title 58
###begin p 59
Whole-cell lysates (50 mug) were separated by 10% SDS-PAGE, and the proteins were transferred to nitrocellulose membrane. The following antibodies were used for Western blotting: anti-cyclin D1 (Thermo Fisher Scientific), anti-AIB1 (BD Biosciences), anti-GDI (RTG Solutions), and anti-Myc (sc-40) and anti-beta-tubulin (sc-9104; both from Santa Cruz Biotechnology, Inc.).
###end p 59
###begin title 60
Cell proliferation assays
###end title 60
###begin p 61
###xml 30 34 30 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">puro</sub>
###xml 61 65 61 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">puro</sub>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
Cells were infected with pMSCVpuro-miR-17/20 cluster or pMSCVpuro empty vector. After puromycin selection, 4 x 104 cells per milliliter were seeded into 6-well plate in triplicate, and the cell number was counted every day for 3-4 d under microscope using a hemocytometer. For the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay, 4 x 103 cells per well were seeded into a 96-well plate in triplicate, and after a 24-h culture, the cell growth was measured by MTT bromide assay.
###end p 61
###begin title 62
Colony formation assay
###end title 62
###begin p 63
The same amount of miR-17/20 overexpression MCF-7 cells and control cells were plated in triplicate in a 6-well plate in puromycin-containing medium. After incubation at 37degreesC for 7-10 d, the colonies were stained with Crystal Violet solution (Allied Chemical Corporation) in methanol for 15-30 min. Colonies >50 mum in diameter were counted.
###end p 63
###begin title 64
Cell cycle analysis
###end title 64
###begin p 65
Cells were starved in DME supplemented with 5% charcoal-stripped serum. After 48 h, medium was changed with DME with 10% normal FBS. Cells were harvested at different time points, and cell cycle parameters were determined using laser scanning cytometry. Cells were processed by standard methods by using propidium iodide staining of cell DNA. 10,000 cells per sample were analyzed by flow cytometry with a FACScan flow cytometer (BD Biosciences). Histograms were analyzed for cell cycle compartments using ModFit version 2.0 (Verity Software House).
###end p 65
###begin title 66
Chromatin immunoprecipitation
###end title 66
###begin p 67
###xml 152 173 152 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Weinmann et al., 2001</xref>
MCF-10A cells were cross-linked with formaldehyde (final concentration of 1%), and chromatin immunoprecipitation was performed as described previously (Weinmann et al., 2001) using anti-cyclin D1 antibody (SC-450; Santa Cruz Biotechnology, Inc.). Real-time PCR was performed using the SYBR green PCR Master Mix kit (Applied Biosystems) to amplify the immunoprecipitated DNA. Sequences of primers derived from the genomic region upstream of the miR-17/20 cluster are provided in Table S1 (available at ).
###end p 67
###begin title 68
Online supplemental material
###end title 68
###begin p 69
###xml 397 400 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 439 444 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc</italic>
###xml 58 63 <span type="species:ncbi:9606">human</span>
Fig. S1 shows the low miR-17-5p and miR-20a expression in human breast cancer cell lines. Fig. S2 shows the cell cycle analysis of miR-17/20-transduced MCF-10A and BT474 cells. Fig. S3 shows that inhibition of endogenous miR-17/20 by anti-miR-17-5p and anti-miR-20a increased cyclin D1 expression in MCF-7 cells. Fig. S4 shows overexpression of cyclin D1 in the MSCV-cyclin D1-transduced cyclin D1-/- MEFs. Fig. S5 shows the inhibition of c-myc expression by the miR-17/20 cluster in MCF-7 cells. Table S1 shows primer sequences for real-time PCR amplification of cyclin D1 chromatin immunoprecipitation assay. Online supplemental material is available at .
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
[Supplemental Material Index]
###end title 71
###begin p 72
###xml 274 283 274 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 269 273 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 284 299 <span type="species:ncbi:10090">transgenic mice</span>
The miRNA chip analysis was performed by the Nucleic Acid Facility of Kimmel Cancer Center, Thomas Jefferson University. We thank Dr. Joshua Mendell and Dr. Andrei Thomas-Tikhonenko for providing the miR-17/20 cluster expression vector, Dr. Andrew Arnold for providing MMTV-cyclin D1 transgenic mice, and Dr. Renato Baserga and Dr. Nicole Willmarth for giving good suggestions. We thank the Division of Biostatistics at Thomas Jefferson University for help in analyzing data.
###end p 72
###begin p 73
This work was supported in part by National Institutes of Health grants R01CA70896, R01CA75503, R01CA86072, and R01CA107382 (to R.G. Pestell). The Kimmel Cancer Center was supported by the National Institutes of Health Cancer Center Core grant P30CA56036 (to R.G. Pestell). This project is funded in part from the Dr. Ralph and Marian C. Falk Medical Research Trust and a grant from the Pennsylvania Department of Health (to R.G. Pestell and C. Wang). The Pennsylvania Department of Health specifically disclaims responsibility for an analysis, interpretations, or conclusions. There are no conflicts of interest associated with this manuscript.
###end p 73

